CAV1 and neoplasm: Using log rank test statistics from the Cox model24, we calculated an optimal cut-off point for the plasma Cav-1-sphingolipid signature that would yield the greatest difference between subjects on AS that exhibited disease progression (defined as upgrading of Gleason score and/or increased tumor volume) from those that did not.